-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
San Francisco, USA and Suzhou, China September 24, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the treatment of tumors, metabolic diseases, etc.
The study (CIBI112A201) is a multicenter, randomized, double-blind, parallel, placebo-controlled phase 2 clinical study evaluating the effectiveness and safety of subcutaneous injection of IBI112 at different doses in the treatment of moderate to severe plaque psoriasis
The main investigator of the study, Professor Zhang Jianzhong from Peking University People’s Hospital pointed out: “The pathogenesis of psoriasis is complicated and difficult to treat.
Dr.
About IBI112
IBI112 (recombinant anti-interleukin 23p19 subunit antibody injection) is a monoclonal antibody independently developed by Innovent with independent intellectual property rights, which specifically binds to IL-23p19 subunit
About psoriasis
Psoriasis is an immune-mediated chronic, recurrent, inflammatory, and systemic disease that interacts with genetics and the environment.
About Cinda Bio
"Starting from the letter, reaching the line", to develop high-quality biological drugs that the common people can afford is the ideal and goal of Cinda Bio
Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model
Cinda Bio has established an internationally advanced high-end biopharmaceutical development and industrialization talent team, including many returned experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center and Hanmi of South Korea.
Forward-looking statement
The information published in this press release may contain certain forward-looking statements
These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management on future affairs at the time the statement is made
Source: Cinda Bio
